Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–36 of 12 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 3 Interventional Accepts healthy volunteers Results available

HerpeVac Trial for Young Women

NCT00057330
Conditions
Herpes Simplex Infection
Interventions
HSV vaccine or SB208141, GSK Biologicals' glycoprotein D (gD)-Alum/3-deacylated form of Monophosphoryl Lipid A (MPL) candidate genital herpes vaccine, Havrix™, GlaxoSmithKline (GSK) Biologicals' licensed Hepatitis A vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 30 Years · Female only
Enrollment
8,323 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
67
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 56 more
Conditions
Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma, Oligodendroglioma, Anaplastic Oligodendroglioma of Brain (Diagnosis), Mixed Oligo-Astrocytoma, Ependymoma, Ganglioglioma, Pylocytic/Pylomyxoid Astrocytoma, Brain Tumor, Glioma, Brain Cancer, Glioblastoma, Glioblastoma Multiforme
Interventions
rQNestin, Cyclophosphamide, Stereotactic biopsy
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
5
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more
Completed No phase listed Observational Results available

Clinical Evaluation of the Sentosa SA HSV1/2 Qualitative PCR Test

NCT02685956
Conditions
Herpes Simplex
Interventions
Vela Sentosa SA HSV1/2 Qualitative PCR Test
Device
Lead sponsor
Vela Diagnostics
Industry
Eligibility
Not listed
Enrollment
2,295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
9
States / cities
Tampa, Florida • Springfield, Massachusetts • Royal Oak, Michigan + 6 more
Conditions
Recurrent Malignant Glioma, Glioblastoma Multiforme of Brain, Gliosarcoma of Brain, Anaplastic Astrocytoma of Brain
Interventions
C134 Re-Administration
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Hsv 1 and 2 Gowey Protocol Versus Placebo

NCT01477879
Conditions
Herpes
Interventions
Versabase gel with sarracenia purpurea 20% liquid extract, placebo (versabase gel only)
Other
Lead sponsor
Naturopaths International
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Flagstaff, Arizona
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Hand Sanitizer Use for Herpes Simplex Virus-1

NCT06135844
Conditions
Virus, HSV-1, Herpes Simplex 1, Herpes Simplex Labialis
Interventions
Purell Hand Sanitizer, Medical Grade Mineral Oil
Drug
Lead sponsor
Leciel Bono
Other
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Pocatello, Idaho • St. George, Utah
Conditions
HSV
Interventions
Benzoyl Peroxide 10% Bar, Placebo
Drug · Other
Lead sponsor
Greg Bew
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Evans, Georgia
Conditions
Autosomal Recessive Ichthyosis
Interventions
KB105, Placebo
Biological · Other
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
6 Months and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rancho Santa Margarita, California
Conditions
Melanoma (Skin)
Interventions
adenovirus RSV-TK, ganciclovir
Biological · Drug
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
3
States / cities
Bethesda, Maryland • Houston, Texas
Completed Phase 1Phase 2 Interventional Results available

A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients

NCT03536143
Conditions
Dystrophic Epidermolysis Bullosa
Interventions
Topical beremagene geperpavec, Placebo gel
Biological
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
2 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Stanford, California
Conditions
Urinary Bladder, Overactive, Spinal Cord Injury
Interventions
Urodynamics, EG110A, Patient-reported Outcome
Other · Drug
Lead sponsor
Cyllene Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
4
States / cities
Downey, California • Ann Arbor, Michigan • Philadelphia, Pennsylvania + 1 more
Conditions
TGM-1 Related Autosomal Recessive Congenital Ichthyosis
Interventions
KB105
Biological
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Chicago, Illinois • Philadelphia, Pennsylvania